How much did Concord Biotech's profit and revenue fall in FY26?

Consolidated net profit fell 30% to ₹259.22 crore from ₹371.64 crore in the prior year. Revenue from operations contracted 12% to ₹1,054.89 crore.

What caused the exceptional items?

The company booked ₹3.27 crore in exceptional items due to the implementation of new national labour codes. The amount is small relative to the overall profit decline.

What shareholder return did the board announce?

The board recommended a final dividend of ₹7.55 per equity share. The filing does not specify the yield or total payout amount.

Did the company make any board changes?

Yes. The board approved the appointment of Mrs. Ekta Gupta as an independent director for a five-year term starting June 2026.

Earnings · Pharmaceuticals · Mid cap

Concord Biotech profit falls 30% as revenue shrinks in FY26

Consolidated net profit dropped to ₹259.22 crore from ₹371.64 crore. Revenue from operations contracted 12%.

— 3 earlier stories on Concord Biotech Ltd. →

CONCORDBIO By Tipsheet Editorial 29 May 2026 · 7:53 PM IST Verify on BSE · NSE

Mkt cap₹12,570 cr

P/E48.18×

ROE20.50%

Debt / eq.0.00

Div yld0.63%

-30% Year-on-year decline in consolidated net profit.

What's new

FY26 consolidated net profit fell 30% to ₹259.22 crore on a 12% revenue decline to ₹1,054.89 crore.
The company booked ₹3.27 crore in exceptional costs from the implementation of new national labour codes.
The board recommended a final dividend of ₹7.55 per share and appointed a new independent director.

Why this matters

A 30% profit drop on 12% lower revenue signals margin compression far beyond the one-time labour-code costs. The core biopharma business shrank, and profitability fell faster than the top line.

What we're watching

Management commentary on the drivers behind the 12% revenue contraction.
Performance of the new injectable facility amid the broader decline.
Whether FY27 guidance addresses the operational headwinds.

The full read

Concord Biotech's FY26 results show a business in contraction. Revenue fell 12% to ₹1,054.89 crore, and net profit dropped 30% to ₹259.22 crore. The company booked ₹3.27 crore in exceptional costs from new labour codes, but these charges are a minor factor in the overall decline. The primary driver is shrinking operations. The board's ₹7.55 per share dividend recommendation is a routine gesture amid the weak performance. The appointment of a new independent director is a secondary event. The core takeaway is clear: the business did less in FY26, and profitability fell faster than revenue.

Questions answered

How much did Concord Biotech's profit and revenue fall in FY26?: Consolidated net profit fell 30% to ₹259.22 crore from ₹371.64 crore in the prior year. Revenue from operations contracted 12% to ₹1,054.89 crore.
What caused the exceptional items?: The company booked ₹3.27 crore in exceptional items due to the implementation of new national labour codes. The amount is small relative to the overall profit decline.
What shareholder return did the board announce?: The board recommended a final dividend of ₹7.55 per equity share. The filing does not specify the yield or total payout amount.
Did the company make any board changes?: Yes. The board approved the appointment of Mrs. Ekta Gupta as an independent director for a five-year term starting June 2026.

Mentioned: Concord Biotech Ltd. · FY26 · ₹259.22 crore net profit

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on CONCORDBIO →

29 May 2026 · 7:53 PM IST Concord Biotech profit falls 30% as revenue shrinks in FY26
1d ago Concord Biotech wins USFDA nod for generic transplant drug
5d ago Concord Biotech's profit falls 30% on a 12% revenue slide
5d ago Concord Biotech profit drops 30% on 11% revenue fall